Select language


Bracco and Dompé: an all-Italian agreement

Milano , 11/18/2016

Bracco and Dompé announce that they have signed an agreement through which the Pharma Division of the Bracco Group will become part of the Italian Biopharmaceutical group led by Sergio Dompé. The closing is scheduled to take place before the end of the year.

The pharmaceutical division of Bracco, whose 2016 turnover is anticipated to be 80 million euros (equal to 6% of the Group's total sales), is present on the Italian market exclusively, with a product portfolio including both prescription drugs in the main therapeutic sectors such as the gastrointestinal, neurological, endocrinological and cardiovascular sectors, and over-the-counter products and supplements, with certain very well-known brand names.

In a competitive and constantly evolving business environment, it is necessary to build a critical mass; therefore, this deal with another leading company such Dompé represents an opportunity which will ensure continuity and the presence of our prestigious product list on the market”, explains Diana Bracco, chair and managing director of the Group of the same name, a world leader in the diagnostic imaging field, with a direct presence in all the major markets. “We will now continue with an ever greater focus on and commitment to the Group's core business, with large investments in our massive Italian plants, in the development of our portfolio and of our geographical presence, and in Research and Development where we already currently invest around 10% of turnover.

The Bracco Group, which owns research centres in Colleretto Giacosa, Geneva, Minneapolis and Princeton, produces contrast media and solutions for all diagnostic techniques:  x-rays (including computed tomography - CT), magnetic resonance imaging (MRI), ultrasound (US) and nuclear imaging (NI). Bracco's product range also includes advanced medical devices and systems for the automatic administration of contrast media for cardiovascular procedures through its American subsidiary, Acist.

“The agreement with Dompé is the climax of an all-Italian industrial project that promotes the values and traditions of two prestigious companies that have helped to write important pages in the history of Italian pharmaceuticals”, sums up Diana Bracco.

This is an operation that, for me, constitutes a milestone and the completion of a union between two business cultures founded on values in which, as an entrepreneur, I firmly believe – states Sergio Dompé, chairman of the Dompé group. “For our company, it represents the confirmation of a model based on the strength of tradition and an on-going quest for innovation. I am convinced that this step will give an added boost to the Group's industrial design, as part of an approach of strategic development, on various fronts, that has always distinguished Dompé's business”.

Bracco and Dompé: an all-Italian agreement

Bracco WorldWide

The Bracco Group,
through its subsidiary
Bracco Imaging
operates throughout
the world both directly
or indirectly.

Read more

Our History

The Bracco Group
exists since 1927,
when Elio Bracco
founded the Italian
E. Merck company

Read more


The Bracco Group
operates through its
three business units.

Read more